Product label
Approved product label
People meeting labeled weight-management or obstructive-sleep-apnea criteria; other approved products have different indications.
Reported findings. In a 72-week randomized trial of 2,539 adults with obesity, or overweight plus a weight-related condition, without type 2 diabetes, estimated average weight loss was 15.0%, 19.5% and 20.9% in the assigned 5, 10 and 15 mg weekly tirzepatide study groups, versus 3.1% with placebo. Doses increased gradually, and all groups received diet and physical-activity support. These are study results, not dosing advice.
Nonresponse. At least 5% weight loss was reached by 85.1%, 88.9% and 90.9% of the respective treatment groups versus 34.5% with placebo. Some participants did not reach that threshold; group averages do not predict an individual result.
Harms. Gastrointestinal reactions, pancreatitis and dehydration-related kidney injury are among label warnings.
Limits. Labeled preparation only; marketed variants do not inherit approval. This result concerns the studied subcutaneous preparation and population; it does not establish equivalence of compounded or research products. Missing week-72 weights were estimated in the analysis. Weight change does not establish a food-noise or personal quality-of-life benefit.
Preparation: Zepbound; Mounjaro is a separate labeled product. Route: subcutaneous
Read original source ↗Editorial review 2026-10-12. Clinician review pending.